Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo sales are being driven by growth in demand for non-melanoma skin indications, coupled with increased utilization in both monotherapy and chemotherapy combination settings in lung cancer.

“Checkpoint inhibitor resistance remains a significant challenge for patients with advanced cancer, with limited treatment options beyond chemotherapy or clinical ... solnerstotug and Libtayo ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab ... rash, and joint pain. Chemo is the standard treatment when you don't have a gene change or high PD-L1.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small ... Sequencing the novel drug, THIO, with Libtayo tended to be ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing disease prevalence, advancements in diagnostic techniques, and the introduction ...

In the EU, Keytruda is used in combination with fluoropyrimidine and platinum-containing chemotherapy as a first-line treatment for patients with locally advanced unresectable or metastatic gastric or ...

Patients with pathologically confirmed solid tumors were treated with ICIs consisting of anti-PD-1/PD-L1 blockade (nivolumab [Opdivo], pembrolizumab [Keytruda], atezolizumab [Tecentriq], cemiplimab ...